Drugs / GamTBvac
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03255278 | Jan → Dec 2017 | tuberculosis | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03878004 | Dec 2018 → Dec 2019 | — | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04975737 | Jan 2022 → Dec 2026 expected | tuberculosis | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GamTBvac | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04975737 ↗ |
| Modality | Vaccine | “GamTBvac" - a recombinant subunit vaccine against the tuberculosis” NCT03255278 ↗ |
| Route | Subcutaneous | “that is applied for the preparing of the solution for a subcutaneous administration” NCT03255278 ↗ |